GSK plc (NYSE:GSK) Stake Cut by Sanibel Captiva Trust Company Inc.

Sanibel Captiva Trust Company Inc. decreased its holdings in shares of GSK plc (NYSE:GSK) by 2.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,351 shares of the pharmaceutical company’s stock after selling 380 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in GSK were worth $668,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Register Financial Advisors LLC bought a new position in GSK in the 1st quarter worth about $31,000. Ashton Thomas Private Wealth LLC bought a new stake in GSK during the 2nd quarter valued at $37,000. Richardson Financial Services Inc. acquired a new position in GSK during the 4th quarter worth $40,000. PrairieView Partners LLC bought a new position in shares of GSK in the second quarter worth $47,000. Finally, Triad Wealth Partners LLC acquired a new position in shares of GSK during the second quarter valued at $49,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Activity at GSK

In related news, major shareholder Plc Gsk bought 2,791,930 shares of the business’s stock in a transaction on Friday, September 27th. The shares were bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is owned by company insiders.

GSK Stock Performance

Shares of NYSE GSK opened at $38.82 on Friday. GSK plc has a one year low of $33.67 and a one year high of $45.92. The business’s 50-day moving average price is $41.50 and its two-hundred day moving average price is $41.39. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. The company has a market capitalization of $80.45 billion, a P/E ratio of 15.65, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. Analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were issued a dividend of $0.3843 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.96%. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is currently 60.89%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Jefferies Financial Group lifted their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.